We also specialize in providing CalliSarc®,
At CalliFarma Therapeutics, we strive to advance the frontiers of medical and cosmetic innovation by tapping into the extraordinary potential of nature’s own healing agents. One such agent is the crude Larval Excretions/Secretions (LES) produced by Lucilia sericata and related blowfly species. Historically, LES research was limited by the scarcity and variability of the raw material, as only a few specialized facilities produced medical-grade maggots and none focused on high-quality LES extracts at scale.
A 100% Green, Sustainable Manufacturing Model
By integrating industrial maggot rearing and the production of our proprietary CalliSarc® into a single workflow, we eliminate supply chain hurdles, ensure reproducible quality, and create a 100% “green” and sustainable process. This closed-loop model allows researchers and clinicians to transition from small-scale experiments to clinical trials with reliable, consistent batches of LES. No more waiting on unstable samples or losing time and resources on inconsistent material. With CalliSarc®, the potential therapeutic and cosmetic benefits of LES can finally be explored in depth.
Untapped Opportunities for Medical & Cosmetic Applications
LES has demonstrated a wide spectrum of beneficial activities:(for full bibligraphy see: Works on larval secretion/excretion)
Chronic Wound Healing: Accelerated wound closure, enhanced granulation tissue formation, and improved angiogenesis. Bexfield et al., Microbes and Infection, 2008, DOI: https://doi.org/10.1177/039139880903200904
Debridement & Tissue Regeneration: Proteolytic enzymes (serine proteases) efficiently remove necrotic tissue, supporting sterile and effective wound bed preparation. Pöppel et al., Insect Biochem Mol Biol, 2016 https://doi.org/10.1016/j.ibmb.2015.11.012(2016)
Anti-biofilm & Antimicrobial Effects: Disruption of Staphylococcus aureus and Pseudomonas aeruginosa biofilms; broad-spectrum antibacterial activity, including against MRSA. van der Plas et al., J Antimicrob Chemother, 2008 https://doi.org/10.1016/j.micinf.2007.01.008
Anti-inflammatory Properties: Reduction of pro-inflammatory cytokines (e.g., IL-6, TNF-α), lessening excessive inflammation in chronic wounds. Honda et al., Am J Physiol Cell Physiol, 2011 https://doi.org/10.1152/ajpcell.00065.2011
Cosmetic and Dermatological Applications: Potential for improved skin texture, controlled exfoliation via enzymatic action, and overall skin health due to balanced microbiome interactions. Tombulturk & Kanigur-Sultuybek, Wound Repair Regen, 2021 https://doi.org/10.1111/wrr.12961
Photo materials on the effect of the CalliSarc analog (ENTOMIX®)
Clinical studies conducted in St. Petersburg (Russia) at Sokolov Clinical Hospital and the Dzhanelidze Research Institute of Emergency Care on diabetic ulcer, burns and pyoderma:
Future R&D Directions with CalliSarc®
- Advanced Wound Dressings: Stable ointments and gels for diabetic foot ulcers, pressure ulcers, and venous leg ulcers.
- Biofilm-Resistant Implants & Medical Devices: Coatings leveraging anti-biofilm properties of LES.
- Anti-Inflammatory Therapies: Topical treatments that modulate inflammation in chronic skin conditions (eczema, psoriasis).
- Skin Care & Aesthetics: Gentle enzymatic exfoliation and microbiome-friendly properties for innovative cosmetic products.
Order and Inquiry
Ready to explore the potential of CalliSarc® for your research or clinical pipeline? Contact us and place your order for high-quality LES samples produced under our unique, sustainable workflow.